Baxter International Inc.
BAX (NYSE)
The investment currently offers a modest dividend yield of 0.15% and a 1-year return of 4.42%, but investors should be cautious due to a significant 5-year decline of nearly 71%. Analysts have set a median 12-month price target of $25, with a range between $21 and $28, reflecting a cautious outlook with a collective rating of 'C' from firms like Stifel and Wells Fargo. This suggests a potential for recovery, yet highlights the importance of careful consideration before investing.
Pros:
- Consistent dividend payments
- Diverse product portfolio in healthcare
Cons:
- Significant decline in 5-year returns
- Market performance concerns
Baxter International Inc. may appeal to investors seeking exposure to the healthcare sector with a modest dividend yield and short-term recovery potential, but the significant long-term decline warrants careful consideration. Those with a higher risk tolerance and a focus on turnaround opportunities may find it suitable, while more conservative investors should weigh the potential risks associated with its recent performance.